NURPF (Neuren Pharmaceuticals) FFO


NURPF Neuren Pharmaceuticals Ltd NURPF
49 GF Score
Price $9.27
GF Value $4.62
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

NURPF
49GF Score
Neuren Pharmaceuticals Ltd NURPF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuren Pharmaceuticals (NURPF) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of $9.27 is trading 100.6% above its estimated GF Value™ of $4.62. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NURPF:

  • FFO:
  • GF Value™: $4.62 vs. price of $9.27 (100.6% above fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the NURPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NK9:GermanyNEU:Australia
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
49GF Score

Get the complete analysis for NURPF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.27
Price
$4.62
GF Value